Tempus AI Buys Personalis in $1.5B Deal to Advance Blood-Based Cancer Detection
The deal combines advanced cancer diagnostics with Tempus’ AI platform for improved surveillance.
/ 2 items
The deal combines advanced cancer diagnostics with Tempus’ AI platform for improved surveillance.
Personalis announces Medicare coverage for its NeXT Personal MRD test, helping Stage I-III lung cancer patients detect residual disease early and improve care.